These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
481 related articles for article (PubMed ID: 31336602)
21. Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations. Gururaj AE; Rayala SK; Vadlamudi RK; Kumar R Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1001s-1007s. PubMed ID: 16467116 [TBL] [Abstract][Full Text] [Related]
22. IL-33 facilitates endocrine resistance of breast cancer by inducing cancer stem cell properties. Hu H; Sun J; Wang C; Bu X; Liu X; Mao Y; Wang H Biochem Biophys Res Commun; 2017 Apr; 485(3):643-650. PubMed ID: 28216163 [TBL] [Abstract][Full Text] [Related]
23. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells. Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106 [TBL] [Abstract][Full Text] [Related]
24. Endocrine Therapy of Estrogen Receptor-Positive Breast Cancer Cells: Early Differential Effects on Stem Cell Markers. Leung EY; Askarian-Amiri ME; Sarkar D; Ferraro-Peyret C; Joseph WR; Finlay GJ; Baguley BC Front Oncol; 2017; 7():184. PubMed ID: 28929082 [TBL] [Abstract][Full Text] [Related]
25. WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines. Sikora MJ; Jacobsen BM; Levine K; Chen J; Davidson NE; Lee AV; Alexander CM; Oesterreich S Breast Cancer Res; 2016 Sep; 18(1):92. PubMed ID: 27650553 [TBL] [Abstract][Full Text] [Related]
26. Endocrine Resistance in Hormone Receptor Positive Breast Cancer-From Mechanism to Therapy. Rani A; Stebbing J; Giamas G; Murphy J Front Endocrinol (Lausanne); 2019; 10():245. PubMed ID: 31178825 [TBL] [Abstract][Full Text] [Related]
27. A novel oncogenic role of inositol phosphatase SHIP2 in ER-negative breast cancer stem cells: involvement of JNK/vimentin activation. Fu CH; Lin RJ; Yu J; Chang WW; Liao GS; Chang WY; Tseng LM; Tsai YF; Yu JC; Yu AL Stem Cells; 2014 Aug; 32(8):2048-60. PubMed ID: 24802135 [TBL] [Abstract][Full Text] [Related]
28. MicroRNAs, a subpopulation of regulators, are involved in breast cancer progression through regulating breast cancer stem cells. Fan X; Chen W; Fu Z; Zeng L; Yin Y; Yuan H Oncol Lett; 2017 Nov; 14(5):5069-5076. PubMed ID: 29142594 [TBL] [Abstract][Full Text] [Related]
29. Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals. Szostakowska M; Trębińska-Stryjewska A; Grzybowska EA; Fabisiewicz A Breast Cancer Res Treat; 2019 Feb; 173(3):489-497. PubMed ID: 30382472 [TBL] [Abstract][Full Text] [Related]
30. Cytokines, breast cancer stem cells (BCSCs) and chemoresistance. Chen W; Qin Y; Liu S Clin Transl Med; 2018 Sep; 7(1):27. PubMed ID: 30175384 [TBL] [Abstract][Full Text] [Related]
31. Plumbagin inhibits cancer stem-like cells, angiogenesis and suppresses cell proliferation and invasion by targeting Wnt/β-catenin pathway in endocrine resistant breast cancer. Sakunrangsit N; Ketchart W Pharmacol Res; 2019 Dec; 150():104517. PubMed ID: 31693936 [TBL] [Abstract][Full Text] [Related]
32. Regulation of Bcl-2 Family Proteins in Estrogen Receptor-Positive Breast Cancer and Their Implications in Endocrine Therapy. Kawiak A; Kostecka A Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053443 [TBL] [Abstract][Full Text] [Related]
33. Molecular Changes During Breast Cancer and Mechanisms of Endocrine Therapy Resistance. Radhi S Prog Mol Biol Transl Sci; 2016; 144():539-562. PubMed ID: 27865467 [TBL] [Abstract][Full Text] [Related]
34. Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer. Iida M; Tsuboi K; Niwa T; Ishida T; Hayashi SI Breast Cancer; 2019 May; 26(3):272-281. PubMed ID: 30328006 [TBL] [Abstract][Full Text] [Related]
35. Targeting Cellular Signaling Pathways in Breast Cancer Stem Cells and its Implication for Cancer Treatment. Pires BR; DE Amorim ÍS; Souza LD; Rodrigues JA; Mencalha AL Anticancer Res; 2016 Nov; 36(11):5681-5691. PubMed ID: 27793889 [TBL] [Abstract][Full Text] [Related]
36. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer. Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191 [TBL] [Abstract][Full Text] [Related]
37. Overcoming endocrine resistance in hormone receptor-positive breast cancer. AlFakeeh A; Brezden-Masley C Curr Oncol; 2018 Jun; 25(Suppl 1):S18-S27. PubMed ID: 29910644 [TBL] [Abstract][Full Text] [Related]
38. Lactate Dehydrogenase-A (LDH-A) Preserves Cancer Stemness and Recruitment of Tumor-Associated Macrophages to Promote Breast Cancer Progression. Wang S; Ma L; Wang Z; He H; Chen H; Duan Z; Li Y; Si Q; Chuang TH; Chen C; Luo Y Front Oncol; 2021; 11():654452. PubMed ID: 34178639 [TBL] [Abstract][Full Text] [Related]
39. The changing role of ER in endocrine resistance. Nardone A; De Angelis C; Trivedi MV; Osborne CK; Schiff R Breast; 2015 Nov; 24 Suppl 2(0 2):S60-6. PubMed ID: 26271713 [TBL] [Abstract][Full Text] [Related]
40. Targeting of the Eukaryotic Translation Initiation Factor 4A Against Breast Cancer Stemness. Sridharan S; Robeson M; Bastihalli-Tukaramrao D; Howard CM; Subramaniyan B; Tilley AMC; Tiwari AK; Raman D Front Oncol; 2019; 9():1311. PubMed ID: 31867270 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]